Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2000
06/06/2000CA2073778C Enzyme treated bcg vaccine and process therefor
06/06/2000CA1341020C Lipoprotein i (ompi) of pseudomonas aeruginosa
06/06/2000CA1341015C Outer membrane protein f of pseudomonas aeruginosa
06/03/2000CA2290847A1 Cosmetic or dermatological composition comprising at least one alkynyl carbamate and at least one polyol
06/02/2000WO2000031532A1 Methods of identifying viral therapeutics
06/02/2000WO2000031288A1 Method for screening cd14 agonist or antagonist
06/02/2000WO2000031280A2 Use of plus-strand synthesis elements in retroviral vectors
06/02/2000WO2000031273A2 Process for oxidising terpenes
06/02/2000WO2000031263A2 Gtpase associated proteins
06/02/2000WO2000031242A2 Engineered cytotoxic ribonuclease
06/02/2000WO2000031141A1 Humanized antibody specific for surface antigen pre-s1 of hbv and preparation method thereof
06/02/2000WO2000031129A1 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
06/02/2000WO2000031127A2 Protein fragments for use in protein targeting
06/02/2000WO2000031120A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
06/02/2000WO2000031115A1 Methods of identifying antigen gene sequences
06/02/2000WO2000031109A1 USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION
06/02/2000WO2000031097A1 13-membered azalides and their use as antibiotic agents
06/02/2000WO2000031085A1 Organophosphorous compounds and the use thereof
06/02/2000WO2000031077A1 Semi-hydrochloride of 8-cyan-1- cyclopropyl -7-(1s,6s-2 ,8-diazabicyclo [4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro -4-oxo-3- quinoline carboxylic acid
06/02/2000WO2000031076A1 Crystal modification b of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo [4.3.0]nonan -8-yl)-6- fluoro-1,4- dihydro-4- oxo-3-quinoline carboxylic acid
06/02/2000WO2000031075A1 Crystal modification a of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo [4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro- 4-oxo-3- quinoline carboxylic acid
06/02/2000WO2000031070A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same
06/02/2000WO2000031068A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants
06/02/2000WO2000031065A1 Compounds having cytokine inhibitory activity
06/02/2000WO2000031062A1 Cycloalkyl-substituted aminomethylpyrrolidine derivatives
06/02/2000WO2000031060A1 Scavenger compounds
06/02/2000WO2000031033A1 Piperidine ccr-3 receptor antagonists
06/02/2000WO2000030678A1 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus
06/02/2000WO2000030677A1 Method of treating viral hemorrhagic fever
06/02/2000WO2000030653A2 Use of phosphonoformic acid derivatives for treating infections
06/02/2000WO2000030649A1 Pharmaceutical compositions containing olanzapine-n-oxide
06/02/2000WO2000030647A1 Compositions comprising cefuroxime axetil
06/02/2000WO2000030625A2 Use of phosphonoformic acid derivatives for treating infections
06/02/2000WO2000030615A1 Method of preparing stable suspensions of insoluble microparticles
06/02/2000WO2000018388A3 Antibiotic compositions for treatment of the eye, ear and nose
06/02/2000WO2000014244A3 Treatment of cervical cancer
06/02/2000WO2000012128A8 Recombinant subunit vaccine against flaviviral infection
06/02/2000WO2000010999A3 New compounds
06/02/2000WO2000009156A9 Non-virulent porphyromonas gingivalis mutant
06/02/2000WO1999063095A9 Nucleic acid vaccines for prevention of flavivirus infection
06/02/2000WO1999061097A9 Alpha emitting constructs and uses thereof
06/02/2000CA2352617A1 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus
06/02/2000CA2352549A1 Use of phosphonoformic acid derivatives for treating infections
06/02/2000CA2352511A1 Use of phosphonoformic acid derivatives for treating infections
06/02/2000CA2352493A1 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
06/02/2000CA2352317A1 Amino alkylphosphonic acid derivatives and their use in treating infections
06/02/2000CA2352144A1 Scavenger compounds
06/02/2000CA2351736A1 Methods of identifying antigen gene sequences
06/02/2000CA2351719A1 Pharmaceutical compositions containing olanzapine-n-oxide
06/02/2000CA2351631A1 Piperidine quaternary salts-ccr-3 receptor antagonists
06/02/2000CA2351630A1 Vector
06/02/2000CA2351497A1 Cycloalkyl-substituted aminomethylpyrrolidine derivative
06/02/2000CA2351470A1 Method of treating viral hemorrhagic fever
06/02/2000CA2351361A1 Gtpase associated proteins
06/02/2000CA2351354A1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
06/02/2000CA2351065A1 Method for screening cd14 agonist or antagonist
06/02/2000CA2350969A1 Compounds having cytokine inhibitory activity
06/02/2000CA2348876A1 Compositions comprising cefuroxime axetil
06/02/2000CA2347940A1 Use of core 2 glcnac transferase inhibitors in treating inflammation
05/2000
05/31/2000EP1004670A2 Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
05/31/2000EP1004592A1 Derivatives of erythromycin, their process of preparation and their application as medicaments
05/31/2000EP1004581A2 Process for the preparation of thalidomide
05/31/2000EP1004580A2 Imides as inhibitors of TNF alpha
05/31/2000EP1004578A2 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
05/31/2000EP1004572A2 Amines as inhibitors of TNF alpha
05/31/2000EP1004314A1 T.d. Polio booster vaccine for a primovaccinated or sensibilisated population
05/31/2000EP1004237A2 Method of introducing material into eggs during early embryonic development
05/31/2000EP1003888A2 Polypeptide nucleic sequences exported from mycobacteria, vectors comprising same and uses for diagnosing and preventing tuberculosis
05/31/2000EP1003875A1 Group a streptococcal vaccines
05/31/2000EP1003874A1 Neisseria lactoferrin binding protein
05/31/2000EP1003851A2 Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy
05/31/2000EP1003844A1 Kinase activating dependent cyclin protein kinases, and their uses
05/31/2000EP1003782A1 Ligand for herpes simplex virus entry mediator and methods of use
05/31/2000EP1003775A2 Hepatitis c inhibitor peptides
05/31/2000EP1003773A1 Ctl epitopes from ebv
05/31/2000EP1003771A1 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
05/31/2000EP1003770A1 Secreted proteins and polynucleotides encoding them
05/31/2000EP1003763A1 83 human secreted proteins
05/31/2000EP1003762A2 Base analogues
05/31/2000EP1003751A1 Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
05/31/2000EP1003747A1 Carbapenems with naphthosultam derivative linked via methylene
05/31/2000EP1003743A1 3,3-disubstituted piperidines as modulators of chemokine receptor activity
05/31/2000EP1003735A1 Quinolizine carboxylic acid derivatives
05/31/2000EP1003724A1 Substituted quinoline derivatives with antiviral action
05/31/2000EP1003548A1 A method of inducing a ctl response
05/31/2000EP1003541A1 Inhibitors of hiv reverse transcriptase
05/31/2000EP1003537A1 Et
05/31/2000EP1003527A1 Polynucleotide compositions
05/31/2000EP1003519A1 Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
05/31/2000EP1003514A1 Cyclic amine modulators of chemokine receptor activity
05/31/2000EP1003509A1 Il-8 receptor antagonists
05/31/2000EP1003497A1 Il-8 receptor antagonists
05/31/2000EP1003492A2 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins
05/31/2000EP1003480A1 Conjugated peptide nucleic acids having enhanced cellular uptake
05/31/2000EP1003476A1 Prolonged release active agent dosage form adapted for gastric retention
05/31/2000EP0690924B1 Anti-microbial agents and screening method therefor
05/31/2000DE19955340A1 CCR-3-Rezeptor-Antagonisten CCR-3 receptor antagonists
05/31/2000DE19854403A1 Phosphororganische Verbindungen und ihre Verwendung Organophosphorus compounds and their use
05/31/2000DE19854402A1 Verwendung von Phosphonameisensäurederivaten zur therapeutischen und prophylaktischen Behandlung von Infektionen Using Phosphonameisensäurederivaten for the therapeutic and prophylactic treatment of infections
05/31/2000DE19854357A1 Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure Semi-hydrochloride of 8-cyano-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo / 4.3.0 / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo -3-quinolinecarboxylic acid
1 ... 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 ... 1798